Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Roche has decided to terminate its global license and collaboration agreement with Repare Therapeutics for the development and commercialization of camonsertib, effective May 7, 2024. Despite this, Repare has fulfilled all obligations and recently received a $40 million milestone payment from Roche. Repare's financial outlook remains stable, with sufficient capital to support operations into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 9:10 pm

Genentech, a Roche subsidiary, announced new 72-week data from BALATON and COMINO studies evaluating Vabysmo for macular edema due to retinal vein occlusion (RVO). The data showed that Vabysmo sustained significant drying of retinal fluid and allowed up to 60% of patients to extend treatment intervals to three or four months. These results will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:33 am

Roche Holdings AG (OTC:RHHBY) has terminated its collaboration with HOOKIPA Pharma Inc (NASDAQ:HOOK) on the HB-700 program for KRAS mutated cancers. HOOKIPA will regain full control of the program in April 2024 and plans to submit an IND in Q1 2024, seeking a new partner. HOOKIPA is refocusing on its HB-200 program for HPV16+ HNSCC and infectious disease programs with Gilead Sciences Inc (NASDAQ:GILD). The company will reduce its workforce by 30% and rebalance costs. HOOKIPA's cash position was $117.5 million as of December 31, 2023, bolstered by Gilead's purchase of 15 million shares in December. HOOKIPA's stock price dropped 15% to $0.59.

Portfolio Pulse from Vandana Singh

January 29, 2024 | 5:55 pm

Roche's Genentech has announced new long-term data for Vabysmo, showing sustained improvements in retinal drying and vision for patients with Retinal Vein Occlusion (RVO). The data indicates that up to 60% of patients could extend treatment intervals to three or four months. Detailed results from two global Phase III RVO studies will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:33 am

Repare Therapeutics has received a $40M milestone payment from Roche following the dosing of the first patient in Roche's TAPISTRY Phase 2 trial under their worldwide license and collaboration agreement for the drug Camonsertib.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:05 pm

AC Immune SA will regain all global rights to its Alzheimer's treatment candidates, crenezumab and semorinemab, after the termination of its collaboration agreements with Genentech, a member of the Roche group. This follows Genentech's decision to return the rights to AC Immune, which could impact the future development and potential commercialization of these drugs.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:33 pm

The European Commission has approved Roche Holdings AG's Tecentriq SC, a subcutaneous injection version of its cancer drug Tecentriq, marking it as the EU's first PD-(L)1 cancer immunotherapy for under the skin injection. Tecentriq SC, which uses Halozyme Therapeutics Inc's Enhanze technology, offers a shorter treatment time compared to the IV infusion method. The approval is based on the IMscin001 study results, and the drug is expected to provide more flexibility for patients and help alleviate healthcare system constraints. Halozyme's shares rose 4.10% on the news.

Portfolio Pulse from Vandana Singh

January 16, 2024 | 4:38 pm

The FDA has approved Merck & Co Inc's Keytruda for a third indication in cervical cancer, in combination with chemoradiotherapy for certain stages. The approval is based on the Phase 3 KEYNOTE-A18 trial, which showed a 41% reduction in the risk of disease progression or death. Keytruda now has 39 indications in the U.S. and is expected to generate nearly $25 billion in sales in 2023. Merck's stock (MRK) saw a slight increase of 0.01% to $118.64.

Portfolio Pulse from Vandana Singh

January 16, 2024 | 4:10 pm

The European Commission has approved Roche's Tecentriq SC, a subcutaneous (SC) formulation of its cancer immunotherapy, which uses Halozyme's ENHANZE technology. This approval marks the EU's first subcutaneous PD-(L)1 cancer immunotherapy for multiple cancer types. The SC injection, which reduces treatment time by approximately 80% compared to standard IV infusion, is preferred by patients and healthcare practitioners due to its convenience and potential time savings for healthcare systems. The approval is based on the Phase IB/III IMscin001 study, demonstrating comparable blood levels of Tecentriq and a consistent safety and efficacy profile to the IV formulation.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 6:57 am

Roche Holdings AG (OTC: RHHBY) has signed a definitive agreement to purchase parts of LumiraDx's point-of-care technology for $295 million, with an additional payment of up to $55 million. LumiraDx Limited (NASDAQ: LMDX) has appointed joint administrators for two subsidiaries, which hold most of the group's assets. The transaction is subject to regulatory approvals and is expected to close by mid-2024. Proceeds will repay loan agreement debts, with no distribution to shareholders. LMDX shares dropped 22.30% in premarket trading.

Portfolio Pulse from Vandana Singh

January 02, 2024 | 12:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.